Přejít k obsahu
Merck

Pulmonary edema measured by MRI correlates with late-phase response to allergen challenge.

Experimental lung research (2015-04-07)
Rhys L Evans, Kumar K Changani, Sarah Hotee, Kashmira Pindoria, Simon Campbell, Anthony T Nials, William R Ford, Kenneth J Broadley, Emma J Kidd
ANOTACE

Asthma is associated with reversible airway obstruction, leucocyte infiltration, airways hyperresponsiveness (AHR), and airways remodeling. Fluid accumulation causes pulmonary edema contributing to airways obstruction. We examined the temporal relationship between the late asthmatic response (LAR) following allergen challenge of sensitized guinea-pigs and pulmonary edema measured by magnetic resonance imaging (MRI). Ovalbumin (OVA) sensitized guinea-pigs received either a single OVA inhalation (acute) or nine OVA inhalations at 48 h intervals (chronic). Airways obstruction was measured as specific airways conductance (sG(aw)) by whole body plethysmography. AHR to inhaled histamine and bronchoalveolar lavage for leucocyte counts were measured 24 h after a single or the final chronic ovalbumin challenges. MRI was performed at intervals after OVA challenge and high-intensity edemic signals were quantified. Ovalbumin caused early bronchoconstriction, followed at 7 h by an LAR and at 24 h AHR and leucocyte influx. The bright-intensity MRI edema signal, peaking at 7 h, was significantly (P < .05) greater after chronic (9.0 ± 0.7 × 10(3) mm(3)) than acute OVA (7.6 ± 0.2 × 10(3) mm(3)). Dexamethasone treatment before acute OVA abolished the AHR and LAR and significantly reduced eosinophils and the bright-intensity MRI edema from 9.1 ± 1.0 to 6.4 ± 0.3 × 10(3) mm(3). We show a temporal relationship between edema and the LAR and their parallel reduction, along with eosinophils and AHR, by dexamethasone. This suggests a close causative association between pulmonary edema and impaired airways function.

MATERIÁLY
Číslo produktu
Značka
Popis produktu

Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Aluminum hydroxide, reagent grade
Sigma-Aldrich
Dexamethasone, tested according to Ph. Eur.
Supelco
Dexamethasone, VETRANAL®, analytical standard
Sigma-Aldrich
Pyrilamine maleate salt
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
Supelco
Pyrilamine maleate, Pharmaceutical Secondary Standard; Certified Reference Material
Mepyramine maleate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Dexamethasone, ≥98% (HPLC), powder
Dexamethasone, British Pharmacopoeia (BP) Assay Standard
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Dexamethasone, United States Pharmacopeia (USP) Reference Standard
Supelco
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material